gbola amusa md cfa head hc research
sale trade et
viral news genet medicin add theme sirna lipid lower
highlight week februari februari buy announc interim clinic
data two phase studi rnai-bas therapeut hypertriglyceridemia
dyslipidemia respect patient least day data compani report robust mean maximum
reduct multipl lipid paramet patient hypertriglyceridemia tg
mg/dl tg patient hypercholesterolemia ldl-c aro-
patient hypertriglyceridemia tg note abund scientif commentari
make comparison among inclisiran drove bn acquisit chardan
top pick medicin compani univers pennsylvania publish result phase trial
approach treat refractori cancer use crispr cell studi evalu autolog cell
target conduct privat parker institut cancer
immunotherapi result show durabl engraft edit cell could detect month
post-infus us result studi demonstr feasibl use crispr gene edit enhanc cell
base therapi freelin privat report result phase i/ii trial gene therapi
hemophilia result patient suggest optimum dose vg/kg potenti deliv
activ catalyst bioscienc buy also report gt-relev data phase iib trial
subq engin therapi dalca cb hemophilia show dalca achiev target level
follow singl iv dose daili subq dose note catalyst preclin develop hemophilia
look forward februari februari februari keyston symposia emerg cellular
therapi held banff program includ crispr therapeut buy buy homolog
medicin unrat intellia buy unrat privat
unrat februari februari annual worldsymposium held
orlando program includ unrat unrat buy chardan
top pick uniqur buy chardan top pick februari miragen unrat
present world congress cutan lymphoma wccl barcelona
unrat report financi result februari et
weekli price move vivo genet medicin vector gt srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
march chardan present sponsor gene therapi genom edit summit host
dr jim wilson dr fulvio mavilio dr andi scharenberg miami
april chardan sponsor arm cell gene meet mediterranean barcelona
gene express control t-cell activ stop-car construct
februari swiss institut bioinformat sib collabor publish natur
engin stop- amen regul small molecul drug -t therapi shown
impress efficaci b-cell malign wider applic addit tumor type limit concern
safeti limit efficaci solid tumor relev attribut stop-car separ antigen bind
pleas refer import disclosur inform regul analyst certif found page report
t-cell activ two fragment recognit signal domain dimer function
modul may disrupt upon addit small-molecul implic design activ t-cell
encod stop-car switched-off limit acut toxic potenti t-cell exhaust associ
chronic antigen stimul latter could theori improv respons solid tumor though hypothesi remain
test rigor human preclin model stop-car-t cell demonstr efficaci psma
antigen least equival convent car-t cell design sib group stop-car
domain modular contain rel short amino acid insert limit transgen antigen
note current studi repres number strategi incorpor switch technolog within cell-bas
immunotherapi us signal grow momentum synthet biolog genet medicin
discuss februari research instanc bellicum pharmaceut unrat advanc program
incorpor safeti and/or small molecul activ switch bluebird bio unrat similarli develop
dimer agent regul immunoreceptor complex daric platform enabl regulat control car-t
activ vivo obsidian privat collabor celgen bristol-my squibb compani
unrat cell-bas therapi tunabl cytokin express addit compani lever synthet biolog
cell-bas immunotherapi space includ poseida therapeut privat senti privat
agtc buy pt recent progress xlrp achromatopsia februari amusa
agtc report result period end decemb via releas recent progress agtc
updat xlrp po po estim
drove increas pt reduc agtc pt back februari research
though thesi posit result drive perform extent play though time
write agtc roughli sinc august upgrad buy continu see reason
 agtc phase i/ii data xlrp good better earlier phase i/ii xlrp data nightstar
 agtc market cap still modest rel roughli million price nightstar could argu
valuabl asset xlrp vs choroideremia unrat might xlrp program
therapeut acquir efficaci particular safeti inflamm
 agtc robust intern manufactur capabl relat requir capsid ophthalmolog
 see downsid limit valuat due agtc clinic asset manufactur cash level
buy pt co provid glimps mad data patient februari naka
arrowhead report financi result period end decemb includ mm
defer net revenu collabor licens agreement aro-hbv
separ releas compani announc result phase trial rnai-bas therapi aro-
hypertriglyceridemia dyslipidemia metabol diseas respect
 compani report substanti knockdown target protein data show mean maximum
 turn led maximum reduct triglycerid led maximum
reduct mean maximum reduct
ldl-c reduct patient alreadi statin inhibitor
maintain buy rate price target see follow togeth reason
 data phase studi expect present scientif
 expect see biopsi data month first cohort patient phase ii open label studi aro-
 believ compani may posit present initi proof-of-concept data clinic
aro- mid-year
program end
announc full-year result includ sale figur provid revenu
guidanc compani previous report onpattro sale approxim mm repres increas
full year onpattro sale mm total revenu quarter mm includ
mm collabor revenu mm givlaari sale
manag provid project onpattro sale rang mm revenu
collabor rang mm compani expect peak loss year
page
maintain buy rate price target basi compani rnai platform compani
posit leader rnai space see signal valid platform
 alnylam gener approv product onpattro givlaari multipl posit phase studi result
 extern partnership includ acquisit medicin compani novarti unrat
agtc buy pt cut rais housekeep updat februari amusa
agtc announc price term mm offer announc term prior model
assumpt mm rais assum base cite file date
februari assumpt made agtc close previous
given announc price updat model mm gross proce offer rather
mm agtc disclosur cash equival januari approxim million
model net cash thu mm mm model earlier
use wacc lever model reflect percept increas risk surround updat thesi
februari thu increas wacc dcf
cash estim revis drove agtc pt back neutral model posit
xlrp achromatopsia franchis basi februari pt upgrad
genet medicin news februari februari
buy announc appoint dr sandra horn board director februari
ortx unrat announc appoint dr steven altschul board director februari
unrat announc public pi trial data dna-bas tx hpv rrp februari
unc publish effect signal cell prolifer antitumor efficaci februari
unrat announc appoint brian mueller act cfo februari
bntx unrat announc commenc public offer american depositari share februari
onc unrat announc sio result feasibl studi electropor devic februari
passag privat file form propos mm maximum aggreg offer ipo februari
onc unrat announc public plasmid dna therapeut tavo mcc februari
freelin privat announc appoint theresa heggi ceo februari
unrat announc price public offer mm common stock februari
askbio privat announc patient dose pi trial aav-bas gt heart failur februari
sirion biotech privat announc licens agreement inproth privat adv vector februari
obsidian privat announc format scientif advisori board februari
unrat announc appoint dr kristin yarema februari
windmil privat collabor preclin car-mil cancer februari
phio unrat announc regist direct offer mm common stock februari
agtc buy announc price public offer mm common stock februari
unrat announc result provid busi updat februari
unrat announc ipo price mm expect gross proce februari
buy announc result provid updat busi oper februari
md publish pi/ii trial car-nk cell posit tumor februari
new england journal medicin research dr kati rezvani group administ cord blood-deriv
natur killer nk cell engin carri construct induc safeti switch
patient relapsed/refractori cancer allogen altern car-t therapi
safeti trial reach maximum toler dose show instanc cytokin releas syndrom
neurotox well-known risk approv car-t therapi
page
efficaci patient achiev object respons complet respons median month
follow-up line approv car-t car-nk could detect peripher blood year infus
respons durabl could conclud respond receiv addit therapi remiss
asset among md anderson car-nk program licens takeda unrat novemb note
nk cell continu emerg therapeut class cord blood potenti sourc off-the-shelf nk
therapi instanc privat gamida cell unrat sourc nk healthi donor
nantkwest unrat employ cell line unrat develop induc pluripot stem cell
ipsc -deriv nk asset buy assess donor-deriv ipsc variant
unrat announc result provid busi updat februari
publish pi trial cell edit refractori cancer februari
research led car-t pioneer dr carl june collabor privat
parker institut cancer immunotherapi publish scienc us clinic trial employ crispr-
base therapi studi evalu autolog cell engin target refractori cancer
assess safeti multiplex edit well evalu activ persist edit cell
product crispr use disrupt endogen cell receptor well gene encod immun
checkpoint effort avoid mispair cell receptor boost anti-tumor immun
studi author demonstr durabl engraft cell bear edit edit cell detect
month post infus impli anti-crispr immun present minim barrier persist ex vivo edit
set addit chromosom transloc could detect case talen-bas car-t
product frequenc declin time suggest confer growth advantag
us studi illustr feasibl appli crispr cell-bas therapi term safeti addit
exampl expect field continu grow see januari research
unrat announc propos offer common stock warrant februari
freelin privat announc result pi/iib trial gt hemophilia februari
compani mention report
page
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur select price move week end feb vivo gm perform vector gt srna mrna ivg
page
week-over-week perform vivo genet medicin vector-bas gt srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm voyag genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note avx bold nite static market cap contribut post acquisit ise ly pa
oxb ln exclud due size and/or histor non-vector-gt and/or ex vivo gt exposur
figur vector-bas gene therapyend-monthli market cap select compani januari present
corpor report factset chardan atrx bntc rgl sln ln exclud due size
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million vector-bas gt sector market cap time includ acquir cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
vector-bas gt comp krystal meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public vector-bas gene therapi companiesw prefer buy buy buy qure buy greater potenti drive upsid space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat vector-bas gt molecular akouo ask cardiac inhibitor estev freelin horama stride tamid taysha gene therapi tenaya note marin lysogen ultragenyx addit unrat public compani pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current
figur vivo gene editingw broadli expect out-performance crispr gene edit sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitbeam privat vivogen edit companiesegenesi emendo therapeut excis recombinet spotlight trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
retin pigmentosa exon mutat
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
